Latest stories on CRVO
CervoMed highlights late-breaking neflamapimod Phase 2a data
TipRanks67 · bullishproduct/pr
CervoMed Inc. (CRVO) files 8-K
SEC 8-K50 · neutralgeneral
CervoMed to Participate in September Investor Conferences
Business Insider56 · neutralgeneral
CervoMed to Participate in September Investor Conferences
GlobeNewswire56 · neutralgeneral
CervoMed price target lowered to $7 from $9 at Roth Capital
The Fly34 · bearishanalyst
CervoMed Inc. (CRVO) files 8-K
SEC 8-K50 · neutralgeneral
Canaccord cuts CervoMed stock price target on funding uncertainty
Investing.com Analyst Ratings34 · bearishanalyst
CervoMed reports Q2 results
Seeking Alpha34 · bearishearnings
CervoMed Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
StockTitan56 · neutralproduct/pr
Cervomed Price Target Lowered To 18 From 27 At Canaccord
The Fly34 · bearishanalyst
CervoMed’s neflamapimod gains UK Innovation Passport
TipRanks63 · neutralproduct/pr
CervoMed Inc. (CRVO) files 8-K
SEC 8-K50 · neutralgeneral
CervoMed Inc. (CRVO) files 8-K
SEC 8-K50 · neutralgeneral
CervoMed Completes Enrollment in Phase 2a Neflamapimod Trial
TipRanks63 · neutralproduct/pr
CervoMed Inc. (CRVO) files 8-K
SEC 8-K50 · neutralgeneral
CervoMed’s DLB Trial Milestone: What CRVO Investors Should Watch Next
TipRanks56 · neutralproduct/pr
CervoMed Raises $10 Million in Direct Offering
TipRanks24 · bearishgeneral
CervoMed Inc. (CRVO) files 8-K
SEC 8-K50 · neutralgeneral